Mfsd2a is a transporter for the essential omega-3 fatty acid docosahexaenoic acid.
Level 5 - mechanism / opinion, no new human data
Mechanistic laboratory study using cell cultures and knockout mouse models without human subjects.
PubMed 24828044 · doi:10.1038/nature13241
What was done
Researchers evaluated the function and substrate specificity of the orphan transporter Mfsd2a using in vitro cell-based transport assays and in vivo Mfsd2a-knockout mouse models. They examined Mfsd2a expression in micro-vessel endothelium, characterized transport mechanics (sodium dependence, chemical form of DHA, acyl chain length, and headgroup requirements), performed brain lipidomic profiling, and tracked brain uptake of radiolabeled lysophosphatidylcholines (LPCs).
What was found
The abstract reports directional findings without numerical values. Mfsd2a is expressed exclusively in blood-brain barrier micro-vessel endothelium and transports DHA in the form of LPC (not unesterified DHA) in a sodium-dependent manner. It also transports other long-chain LPCs (14 or more carbons, such as LPC oleate and LPC palmitate) requiring a phosphor-zwitterionic headgroup. Mfsd2a-knockout mice showed markedly reduced brain uptake of plasma LPC-DHA, reduced brain DHA levels, microcephaly, neuronal loss in the hippocampus and cerebellum, cognitive deficits, and severe anxiety.
Why it matters
This study identifies the primary molecular mechanism by which docosahexaenoic acid crosses the blood-brain barrier, establishing an essential physiological pathway for brain lipid uptake via plasma-derived lysophosphatidylcholines.
Limits
The abstract does not report sample sizes, quantitative effect sizes, or statistical metrics. All findings are derived from rodent models and cell culture systems, limiting direct inferences regarding human transport kinetics and clinical pathology without further clinical validation.
Cited by
- supports DHA is transported across the blood-brain barrier in phospholipid form via the MFSD2A transporter.